EUCTR2013-002513-35-IT进行中（未招募）1 期
A multicenter, prospective, randomized, open label study to assess the effect of serelaxin versus standard of care in acute heart failure (AHF) patients. - RELAX AHF_Pan E
OVARTIS FARMA S.p.A.0 个研究点目标入组 2,685 人开始时间: 2013年11月21日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 2,685
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Systolic blood pressure =125 mmHg
- •- Admitted for AHF
- •- Furosemide at any time between admission and the start of screening
- •- eGFR on admission: =30 and =75 mL/min/1.73 m2
- •Other protocol-defined inclusion criteria may apply.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 617
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 2068
排除标准
- •- Dyspnea (non-cardiac causes)
- •- T >38.5°C
- •- Clinical evidence of acute coronary syndrome
- •- AHF due to arrhythmias, acute myocarditis or cardiomyopathy
- •Other protocol-defined exclusion criteria may apply.
研究者
相似试验
进行中（未招募）
1 期
Effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Acute heart failureEUCTR2013-002513-35-GBovartis Pharma Services AG2,650
进行中（未招募）
1 期
Effect of serelaxin versus standard of care in acute heart failure (AHF) patients.EUCTR2013-002513-35-PLovartis Pharma Services AG3,183
进行中（未招募）
1 期
Effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Acute heart failureEUCTR2013-002513-35-HRovartis Pharma Services AG3,183
进行中（未招募）
1 期
Effect of serelaxin versus standard of care in acute heart failure (AHF) patients.EUCTR2013-002513-35-GRovartis Pharma Services AG2,685
进行中（未招募）
1 期
Effect of serelaxin versus standard of care in acute heart failure (AHF) patients.Acute heart failureEUCTR2013-002513-35-EEovartis Pharma Services AG2,650